Invivyd to Participate in Upcoming Investor Conferences

Group 1 - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [2] - The company utilizes its proprietary INVYMAB™ platform, which integrates advanced viral surveillance, predictive modeling, and antibody engineering to rapidly generate new monoclonal antibodies [2] - In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first monoclonal antibody in a series of innovative candidates [2] Group 2 - Invivyd will present at several upcoming investor conferences, including the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, and the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 [1] - Live webcasts of the presentations will be available on the company's investor website and archived for approximately 90 days [1]